Kyocera to spin off medical business into new subsidiary

** Kyocera Corporation (TSE: 6971) announced it will spin off its medical business into a new, wholly-owned subsidiary, Kyocera Medical Corporation, effective October 1, 2025. The move, structured as a simplified absorption-type company split, aims to enhance agility and specialization within the medical device sector. Kyocera Medical will focus on artificial joints and dental implants, taking over related assets and liabilities currently valued at JPY 29,213 million in current assets and JPY 3,402 million in non-current assets, against current and non-current liabilities of JPY 1,056 million and JPY 38 million respectively. This restructuring will allow Kyocera Medical to respond more effectively to evolving market needs, stringent regulatory requirements, and international standards, while Kyocera Corp remains a shareholder with 100% ownership. Kyocera Medical will be headquartered in Kyoto with JPY 1 in initial capital with plans to increase it to JPY 50 million. Kyocera anticipates the spin-off will be immaterial to its consolidated financial results, and aims to improve the quality of life for patients and contribute to medical care.